APAC IPOs & Placements

Zhen Zhou, Toh

IPOs and Placements coverage across Asia Pacific

Aequitas Research

We cover all listing across the Asia Pacific along with follow-up placements. As of Dec 2020, our team had covered 539 IPOs with a hit rate of 73.5% and 685 placements with a hit rate of 66.8%.

We combine fundamental bottom-up views with our proprietary quantitative framework to provide a holistic coverage across new listings and placements. Our coverage includes pre-IPO notes before the deal is launched, follow-up analysis once the deal is live and post-listing trading analysis as well.

Equity Capital Markets

<p><a href="https://www.smartkarma.com/entities/zai-lab-ltd" target="_blank" data-smartkarma-citation="entities:25877:1" rel="noopener">Zai Lab Ltd (ZLAB US)</a> is looking to raise up to US$750m in its follow-on offering. </p><div><p>We have covered the company's US listing, Hong Kong secondary listing in September 2020, and some of its prior follow-on offerings in:</p></div><div><ul style="list-style-type: disc;">
<li><a href="https://www.smartkarma.com/insights/zai-lab-ipo-experienced-team-promising-in-licensing-drug-pipeline-part-1" target="_blank" rel="noopener">Zai Lab IPO: Experienced Team, Promising In-Licensing Drug Pipeline (Part 1)</a></li>
<li><a href="https://www.smartkarma.com/insights/zai-lab-ipo-thoughts-on-valuation-risks-and-upsides-part-2" target="_blank" rel="noopener">Zai Lab IPO: Thoughts on Valuation, Risks and Upsides (Part 2)</a></li>
<li><a href="https://www.smartkarma.com/insights/zai-lab-placement-beware-of-performance-of-last-deal-despite-decent-fundamentals" target="_blank" rel="noopener">Zai Lab Placement: Beware of Performance of Last Deal Despite Decent Fundamentals</a></li>
<li><a href="https://www.smartkarma.com/insights/zai-lab-placement-positive-development-bodes-well-for-the-deal" target="_blank" rel="noopener">Zai Lab Placement: Positive Development Bodes Well for the Deal</a></li>
<li>
<a href="https://www.smartkarma.com/insights/zai-lab-hk-secondary-listing-large-deal-to-digest-but-past-deals-have-done-well" target="_blank" data-smartkarma-citation="insights:43219" rel="noopener">Zai Lab HK Secondary Listing - Large Deal to Digest but past Deals Have Done Well</a> </li>
<li>
<a href="https://www.smartkarma.com/insights/zai-lab-hk-trading-interest-and-behaviour-in-line-with-huazhu-highest-concentration-so-far" target="_blank" data-smartkarma-citation="insights:43573" rel="noopener">Zai Lab HK Trading - Interest and Behaviour in Line with Huazhu, Highest Concentration so Far</a> </li>
</ul></div>

Zai Lab Ltd (ZLAB US) is looking to raise up to US$750m in its follow-on offering. We have covered the company's US listing, Hong Kong secondary listing in September 2020, and some of its prior follow-on offerings in:
Zai Lab IPO: Experienced Team, Promising In-Licensing Drug Pipeline (Part 1)
Zai Lab IPO: Thoughts on Valuation, Risks and Upsides (Part 2)
Zai Lab Placement: Beware of Performance of Last Deal Despite Decent Fundamentals
Zai Lab Placement: Positive Development Bodes Well for the Deal

Zai Lab HK Secondary Listing - Large Deal to Digest but past Deals Have Done Well 

Zai Lab HK Trading - Interest and Behaviour in Line with Huazhu, Highest Concentration so Far 


Zai Lab Follow-On Offering - Much Better Liquidity and Strong Track Record than a Year Ago

United States

Novocure Limited is an oncology company. The Company researches and develops novel technologies for the treatment of cancer. Novocure serves the healthcare industry worldwide.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Novocure Ltd (NVCR US)

Zai Lab Follow-On Offering - Much Better Liquidity and Strong Track Record than a Year Ago

Zai Lab Ltd (ZLAB US) is looking to raise up to US$750m in its follow-on offering. Track record and liquidity has improved significantly since then.

Zhen Zhou, Toh

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)